Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Summary
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for n...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.